SGK1-IN-4 (compound 17a) is a highly selective, orally active SGK1 inhibitor. SGK1-IN-4 can be used for osteoarthritis research.

SGK1-IN-3 (compound 3a) is a potent and orally active inhibitor of SGK1. The serine/threonine kinase SGK1 is an activator of the β-catenin pathway and a powerful stimulator of cartilage degradation that is found to be upregulated under genomic control in diseased osteoarthritic cartilage. SGK1-IN-3 has the potential for the research of osteoarthritis.

Sanofi-14h is a selective inhibitor of the AGC family kinase SGK3, blocks DMXAA-stimulated IRF3-promoter activity with IC50 of 1.73 uM, inhibits IFNβ production under STING stimulation.